Tigan®
(trimethobenzamide hydrochloride)

Capsules

DESCRIPTION

Chemically, trimethobenzamide HCl is N-[p-[2-(dimethylamino)ethoxy]benzyl]-3,4,5-
trimethoxybenzamide monohydrochloride. It has a molecular weight of 424.93 and the
following structural formula:

\[(\text{CH}_3)_2\text{N}-\text{CH}_2\text{CH}_2\text{OC H}_2\text{NHCOCH}_3 \cdot \text{HCl}\]

Capsules: Each 300-mg Tigan® capsule for oral use contains trimethobenzamide
hydrochloride equivalent to 300 mg. The capsule has an opaque purple cap marked “Tigan”
and an opaque purple body marked “M079”.

Inactive Ingredients: D&C Red No. 28, FD&C Blue No. 1, lactose, magnesium stearate,
starch and titanium dioxide.

CLINICAL PHARMACOLOGY

Mechanism of Action

The mechanism of action of Tigan® as determined in animals is obscure, but may involve the
chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic
impulses are conveyed to the vomiting center; direct impulses to the vomiting center
apparently are not similarly inhibited. In dogs pretreated with trimethobenzamide HCl, the
emetic response to apomorphine is inhibited, while little or no protection is afforded against
emesis induced by intragastric copper sulfate.

Pharmacokinetics

The pharmacokinetics of trimethobenzamide have been studied in healthy adult subjects.
Following administration of 200 mg (100 mg/mL) Tigan I.M. injection, the time to reach
maximum plasma concentration (T_{max}) was about half an hour, about 15 minutes longer for
Tigan 300 mg oral capsule than an I.M. injection. A single dose of Tigan 300 mg oral capsule
provided a plasma concentration profile of trimethobenzamide similar to Tigan 200 mg I.M.
The relative bioavailability of the capsule formulation compared to the solution is 100%. The
mean elimination half-life of trimethobenzamide is 7 to 9 hours. Between 30 – 50% of a
single dose in humans is excreted unchanged in the urine within 48-72 hours. The metabolic
disposition of trimethobenzamide in humans is not known. Specifically, it is not known if active metabolites are generated in humans.

**Special Populations**

**Age**

The clearance of trimethobenzamide is not known in patients with renal impairment. However, it may be advisable to consider reduction in the dosing of trimethobenzamide in elderly patients with renal impairment considering that a substantial amount of excretion and elimination of trimethobenzamide occurs via the kidney and that elderly patients may have various degrees of renal impairment. (See **PRECAUTIONS: General and DOSAGE AND ADMINISTRATION**).

**Gender**

Systemic exposure to trimethobenzamide was similar between men (N=40) and women (N=28).

**Race**

Pharmacokinetics appeared to be similar for Caucasians (N=53) and African Americans (N=12).

**Renal Impairment**

The clearance of trimethobenzamide is not known in patients with renal impairment. However, it may be advisable to consider reduction in the dosing of trimethobenzamide in patients with renal impairment considering that a substantial amount of excretion and elimination of trimethobenzamide occurs via the kidney. (See **PRECAUTIONS: General and DOSAGE AND ADMINISTRATION**).

**INDICATIONS**

*Tigan®* is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.

**CONTRAINdications**

Use of any dosage form in patients with known hypersensitivity to trimethobenzamide is contraindicated.

**WARNINGS**

Caution should be exercised when administering *Tigan®* to children for the treatment of vomiting. Antiemetics are not recommended for treatment of uncomplicated vomiting in
children and their use should be limited to prolonged vomiting of known etiology. There are two principal reasons for caution:

1. The extrapyramidal symptoms which can occur secondary to Tigan® may be confused with the central nervous system signs of an undiagnosed primary disease responsible for the vomiting, e.g., Reye’s syndrome or other encephalopathy.

2. It has been suspected that drugs with hepatotoxic potential, such as Tigan®, may unfavorably alter the course of Reye’s syndrome. Such drugs should therefore be avoided in children whose signs and symptoms (vomiting) could represent Reye’s syndrome.

Tigan® may produce drowsiness. Patients should not operate motor vehicles or other dangerous machinery until their individual responses have been determined.

**Usage in Pregnancy:** Trimethobenzamide hydrochloride was studied in reproduction experiments in rats and rabbits and no teratogenicity was suggested. The only effects observed were an increased percentage of embryonic resorptions or stillborn pups in rats administered 20 mg and 100 mg/kg and increased resorptions in rabbits receiving 100 mg/kg. In each study these adverse effects were attributed to one or two dams. The relevance to humans is not known. Since there is no adequate experience in pregnant or lactating women who have received this drug, safety in pregnancy or in nursing mothers has not been established.

**Usage with Alcohol:** Concomitant use of alcohol with Tigan® may result in an adverse drug interaction.

**PRECAUTIONS**

During the course of acute febrile illness, encephalitides, gastroenteritis, dehydration and electrolyte imbalance, especially in children and the elderly or debilitated, CNS reactions such as opisthotonos, convulsions, coma and extrapyramidal symptoms have been reported with and without use of Tigan® (trimethobenzamide hydrochloride) or other antiemetic agents. In such disorders caution should be exercised in administering Tigan®, particularly to patients who have recently received other CNS-acting agents (phenothiazines, barbiturates, belladonna derivatives). Primary emphasis should be directed toward the restoration of body fluids and electrolyte balance, the relief of fever and relief of the causative disease process. Overhydration should be avoided since it may result in cerebral edema.

The antiemetic effects of Tigan® may render diagnosis more difficult in such conditions as appendicitis and obscure signs of toxicity due to overdosage of other drugs.

**General**

Adjustment of Dose in Renal Failure
A substantial route of elimination of unchanged trimethobenzamide is via the kidney. Dosage adjustment should be considered in patients with reduced renal function including some elderly patients. (See CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).

Geriatric Use

Clinical studies of trimethobenzamide hydrochloride did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Although there are studies reported in the literature that included elderly patients > 65 years old with younger patients, it is not known if there are differences in efficacy or safety parameters for elderly and non-elderly patients treated with trimethobenzamide. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).

ADVERSE REACTIONS

There have been reports of hypersensitivity reactions and Parkinson-like symptoms. There have been instances of hypotension reported following parenteral administration to surgical patients. There have been reports of blood dyscrasias, blurring of vision, coma, convulsions, depression of mood, diarrhea, disorientation, dizziness, drowsiness, headache, jaundice, muscle cramps and opisthotonos. If these occur, the administration of the drug should be discontinued. Allergic-type skin reactions have been observed; therefore, the drug should be discontinued at the first sign of sensitization. While these symptoms will usually disappear spontaneously, symptomatic treatment may be indicated in some cases.

DOSAGE AND ADMINISTRATION

(See WARNINGS and PRECAUTIONS.)

Dosage should be adjusted according to the indication for therapy, severity of symptoms and the response of the patient.

Geriatric Patients

Dose adjustment such as reducing the total dose administered at each dosing or increasing the dosing interval should be considered in elderly patients with renal impairment (creatinine
clearance ≤ 70 mL/min/1.73m²). Final dose adjustment should be based upon integration of clinical efficacy and safety considerations. (See CLINICAL PHARMACOLOGY and PRECAUTIONS).

Patients with Renal Impairment

In subjects with renal impairment (creatinine clearance ≤ 70 mL/min/1.73m²), dose adjustment such as reducing the total dose administered at each dosing or increasing the dosing interval should be considered. (See CLINICAL PHARMACOLOGY and PRECAUTIONS).

CAPSULES, 300 mg

Usual Adult Dosage

One 300 mg capsule t.i.d. or q.i.d.

STORAGE

Store at 25°C (77°F).
Excursions permitted to 15–30°C (59–86°F).
[See USP Controlled Room Temperature]

HOW SUPPLIED

Capsules, 300 mg trimethobenzamide hydrochloride each, bottles of 100
NDC 61570-079-01 300 mg 100’s

Rx Only
Prescribing Information as of August 2007.

Monarch Pharmaceuticals®

Distributed By: Monarch Pharmaceuticals, Inc., Bristol, TN 37620
(A wholly owned subsidiary of King Pharmaceuticals, Inc.)
Manufactured By: King Pharmaceuticals, Inc., Bristol, TN 37620